-+ 0.00%
-+ 0.00%
-+ 0.00%

Mendus Expands NorthX Biologics Collaboration to Produce Memory NK Cell Therapies

PUBT·11/10/2026 07:07:43
Listen to the news
Mendus Expands NorthX Biologics Collaboration to Produce Memory NK Cell Therapies
  • Mendus expanded its NorthX Biologics collaboration to manufacture donor-derived memory NK cell therapies, extending their vididencel manufacturing alliance established in 2023.
  • Vinnova awarded SEK 977,300 to establish the manufacturing platform using proprietary DCOne technology.
  • The therapies target potential treatment of acute myeloid leukemia following stem cell transplantation, separate from the lead vididencel program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mendus AB (publ) published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.